[Clinical study on intervention of liuwei dihuang pill on hormonotherapy in treating nephrotic syndrome].
OBJECTIVE
To observe the intervention of liuwei dihuang pill (LDP) on therapeutic effectiveness and adverse reaction of hormonotherapy in treating nephrotic syndrome.


METHODS
Patients allocated in two groups were medicated with initial dose of prednisone 1 mg/kg once a day at 8 am in the morning. After being medicated for 8 to 12 weeks, the dose of prednisone was decreased by 5.0 mg every 2 weeks till 0.5 mg/kg per day. Then the medication was changed to that two days' dosage orally take once a day with the daily dose reduced by 5.0 mg/kg every 2 to 3 weeks, and maintained at 0.4 mg/kg once every two days. At same time, necessary symptomatic treatment was given. To the treated group oral administration of LDP 8 capsules was given additionally, 3 times per day until prednisone decreased to maintenance dose.


RESULTS
Therapeutic effect in the treated group was significant better than that in the control group (P < 0.05). Urinary protein, plasma albumin, triglyceride (TG) and total cholesterol (TC) in both groups were obviously improved (P < 0.05 or P < 0.01). However, as compared with the control group, the improvement was better, and the recurrent rate was lower (P < 0.05) in the treated group. Scores of Yin-deficiency caused excessive Fire syndrome and incidence rate of adverse reaction in the treated group were lower than those in the control group (P < 0.05 or P < 0.01).


CONCLUSIONS
LDP can markedly improve the therapeutic effectiveness and counteract the adverse reaction of hormonotherapy in treating nephrotic syndrome, and reduce the recurrence of the disease.
Hu
Shun-Jin
SJ
Department of Nephropathy, The First Affiliated Hospital, Anhui TCM University, Hefei 230031. hushunjin@sohu.com
Fang
Qi
Q
Liu
Jia-sheng
JS
Zhang
Li
L
Cao
En-ze
EZ
D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D009765:Obesity / Q000139:chemically induced / Q000517:prevention & control; D008517:Phytotherapy; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D016710:Yin Deficiency / Q000139:chemically induced / Q000517:prevention & control
D004365:Drugs, Chinese Herbal; C476907:liu-wei-di-huang wan; D011241:Prednisone